Search
Urea C-13
go.drugbank.com/drugs/DB09510ApprovedInvestigationalTo detect H. pylori, urea labeled with 13C is swallowed by the patient. … The UBT is indicated to confirm H. pylori infection and to monitor post-treatment for its eradication. Radiolabelled urea is available in two forms as 13C and 14C.
Products: Tablet 100 mg, TAU-KIT® 100 MGAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: CİBİNQO 100 MG FİLM KAPLI TABLET, 28 ADET, CIBINQO® 50 MGTocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET, ACTEMRA 200 MG/10 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 4 ADETKetotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigationalIt has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine]. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.
Products: FUMAST 1 MG/5 ML SURUP, 100 ML, MITOFEN 1 MG/5 ML SURUP 100 MLHexetidine
go.drugbank.com/drugs/DB08958ApprovedWithdrawnA bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene.
Products: VAGI-HEX 10 MG VAJINAL TABLET, 12 ADET, HEKZOTON GARGARA, 100 MLSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesProducts: XADAGO 100 MG TABLETASRECUBIERTAS CON PELÍCULA, Equfina Film coated Tablets 50 mgOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawn[L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation. … and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT3 Receptor AntagonistsProducts: ONZYD 4 MG AGIZDA DAGILAN 10 TABLET, ONZYD 8 MG AGIZDA DAGILAN 10 TABLETPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]
Products: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADETCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Synonyms: [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acidProducts: KENGREXAL 50 MG ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 10 ADETChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnIt belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: ORBİN 250 MG TABLET, 100 ADET, ORBIN 250 MG TABLET, 1000 ADET